Keywords: Liver disease, AASLD, Merck & Co, Boceprivir, Boehringer Ingelheim, Vertex, Telaprevir, Gilead, Viread

Liver disease meeting hears updates on Merck & Co’s boceprevir, Boehringer Ingelheim’s HCV combo, Vertex’ telaprevir and Gilead’s Viread

Article | 02 November 2010

Print This

The American Association for the Study of Liver Disease, currently taking place in Boston, heard final results from US drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in